02148nas a2200193   4500008004100000245010200041210006900143260000900212300001200221490000700233520143900240100002701679700002301706700002401729700002501753700002701778700002501805856012401830       2020                        eng d00aDevelopment of multiple reaction monitoring assay for quantification of carnosine in human plasma0 aDevelopment of multiple reaction monitoring assay for quantifica  cJAN   a763-7690 v103 a<p>Carnosine, a histidine containing dipeptide, exerts beneficial effects by scavenging reactive carbonyl compounds (RCCs) that are implicated in pathogenesis of diabetes. However, the reduced carnosine levels may aggravate the severity of diabetes. The precise quantification of carnosine levels may serve as an indicator of pathophysiological state of diabetes. Therefore, we have developed a highly sensitive targeted multiple reaction monitoring (MRM) method for quantification of carnosine in human plasma samples. Various mass spectrometry parameters such as ionization of precursor, fragment abundance and stability, collision energy, tube lens offset voltage were optimized to develop a sensitive and robust assay. Using the optimized MRM assay, the lower limit of detection (LOD) and limit of quantification (LOQ) for carnosine were found to be 0.4 nM and 1.0 nM respectively. Standard curves were constructed ranging from 1.0 nM to 15.0 mu M and the levels of carnosine in mice and human plasma were determined. Further, the MRM assay was extended to study carnosine hydrolyzing activity of human carnosinases, the serum carnosinase (CN1) and the cytosolic carnosinase (CN2). CN1 showed three folds higher activity than CN2. The MRM assay developed in this study is highly sensitive and can be used for basal plasma carnosine quantification, which can be developed as a novel marker for scavenging of RCCs in diabetes.</p>
1 aPandya, Vaibhav, Kumar1 aSonwane, Babasaheb1 aRathore, Rajeshwari1 aUnnikrishnan, A., G.1 aKumaran, Sangaralingam1 aKulkarni, Mahesh, J.  uhttps://library.ncl.res.in/content/development-multiple-reaction-monitoring-assay-quantification-carnosine-human-plasma01962nas a2200193   4500008004100000245014000041210006900181260000800250300001300258490000700271520124100278100002101519700002301540700001701563700001901580700001801599700001901617856013201636       2026                        eng d00aIntegrative transcriptomics and metabolomics reveal distinct metabolic reprogramming in luminal and triple-negative breast cancer cells0 aIntegrative transcriptomics and metabolomics reveal distinct met  cJAN  aaaiaf0030 v223 a<p>
	Breast cancer subtypes exhibit significant molecular and metabolic heterogeneity, influencing their aggressiveness and therapeutic responses. Among them, triple-negative breast cancer (TNBC) is highly aggressive and often resistant to conventional therapies. To investigate the metabolic programming of this aggressiveness, we conducted an integrated transcriptomics and metabolomics analysis comparing the MCF-7 (luminal A, ER+/PR+) and MDA-MB-231 (TNBC) breast cancer cell lines. Transcriptome analysis of MCF-7 and MDA-MB-231 revealed the differential expression of genes involved in key metabolic pathways. Metabolomics data, further corroborated by transcriptomics, suggest pathway enrichment in beta-alanine, histidine, glutathione, nucleotide metabolism, and the tricarboxylic acid cycle. MDA-MB-231 cells displayed a metabolically aggressive phenotype with enhanced oxidative phosphorylation, redox adaptation, and nucleotide turnover. In contrast, MCF-7 cells showed a more regulated amino acid and redox metabolism profile. The integration of transcriptomic and metabolite profiles highlighted potential metabolic vulnerabilities in TNBC, offering insights into subtype-specific differences at the molecular level.</p>
1 aRanawade, Preeti1 aSonwane, Babasaheb1 aBose, Ganesh1 aJadhav, Revati1 aJoshi, Rakesh1 aMittal, Smriti  uhttps://library.ncl.res.in/content/integrative-transcriptomics-and-metabolomics-reveal-distinct-metabolic-reprogramming-luminal